J07BN04 - Covid-19, Protein Subunit |
Probably not porphyrinogenic |
PNP |
Mono.Rationale
Based on the pharmacokinetics of the protein subunit Covid-19 vaccine, no porphyrinogenic effects are expected.
Mono.ChemicalDescription
Protein subunit vaccine.
Mono.TherapeuticCharacteristics
Indicated for preventing coronavirus disease 2019 (COVID-19) in individuals aged 12 years and older. It is administered by intramuscular injections.
Mono.MetabolismAndPharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Mono.SimilarDrugs
Mono.References
| # | Citation details | PubMed ID |
|---|---|---|
| Government bodies | ||
| 1. | European Medicines Agency (EMA). SmPC Nuvaxovid.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Mono.Tradenames
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax 
Bimervax · Nuvaxovid 
Nuvaxovid 
Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax 
Bimervax · Nuvaxovid · VidPrevtyn Beta 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid · Vidprevtyn Beta 
Bimervax · Nuvaxovid 
Bimervax · Nuvaxovid · VidPrevtyn 
Bimervax · Nuvaxovid 
Vaccines